SLC29A1抗体;SLC29A1 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human placenta and normal kidney tissue, Primary antibody: P11535(SLC29A1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P11535(SLC29A1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P11535(SLC29A1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The SLC29A1 antibody is a key tool for studying the solute carrier family 29 member 1 (SLC29A1), a nucleoside transporter protein also known as equilibrative nucleoside transporter 1 (ENT1). SLC29A1 facilitates the bidirectional transport of nucleosides (e.g., adenosine) and nucleobases across cell membranes, playing a critical role in cellular nucleotide homeostasis, signaling, and drug uptake. It is widely expressed in tissues such as the liver, kidney, brain, and immune cells, and is implicated in physiological processes like cardiovascular regulation, immune response, and cancer progression. Dysregulation of SLC29A1 is linked to chemotherapy resistance, neurological disorders, and inflammatory diseases.

SLC29A1 antibodies are designed to detect endogenous SLC29A1 proteins in applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. These antibodies typically target specific epitopes, such as the N- or C-terminal regions, and are validated for specificity using knockdown/knockout controls. Researchers use them to investigate SLC29A1 expression patterns, subcellular localization (primarily plasma and mitochondrial membranes), and regulatory mechanisms under pathological conditions. Commercial antibodies may vary in host species (e.g., rabbit, mouse), clonality (monoclonal/polyclonal), and conjugation tags (e.g., HRP, FITC). Proper validation ensures reliable results, aiding studies on nucleoside metabolism, drug delivery, and therapeutic targeting of SLC29A1 in diseases like cancer or ischemia.